HCA Healthcare enters its Q1 2026 earnings report with a consensus revenue estimate of $19.1 billion and EPS of $7.19, with the current stock price of $471.18 trading at a significant discount to the average analyst price target of $551.00.
Investors are primarily focused on same-facility equivalent admissions growth, which is projected to rise 2.2% despite mounting policy-driven headwinds in Affordable Care Act (ACA) exchange volumes.
The upcoming results will serve as the first major test for HCA's $400 million operational resiliency program, designed to offset a projected $600 million to $900 million annual impact from insurance exchange attrition. Analysts are also closely monitoring whether historically high occupancy levels, which reached 74% in late 2025, will lead to capacity constraints or if continued network expansion can sustain volume momentum.